IO Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	143.19	142.59	211.53	3.41	7.85
Cash & Cash Equivalents	143.19	142.59	211.53	3.41	7.85
Cash Growth	0.42%	-32.59%	6112.36%	-56.60%	-
Other Current Assets	4.06	5.63	10.21	2.23	1.56
Total Current Assets	147.26	148.22	221.74	5.64	9.4
Property, Plant & Equipment	3.11	3.23	0.16	0	0
Long-Term Investments	0.27	0.27	0.27	0	0
Other Long-Term Assets	0.09	0.08	0.13	0.02	0.02
Total Long-Term Assets	3.46	3.59	0.55	0.02	0.02
Total Assets	150.72	151.81	222.29	5.65	9.42
Accounts Payable	3.88	4	3.93	0.52	1
Current Debt	0.66	0.52	0	0	8.66
Other Current Liabilities	11.18	6.16	6.38	2.53	1.18
Total Current Liabilities	15.72	10.68	10.31	3.05	10.84
Long-Term Debt	1.84	2.28	0	0	0
Other Long-Term Liabilities	0	0	0.06	0	0.05
Total Long-Term Liabilities	1.84	2.28	0.06	0	0.05
Total Liabilities	17.56	12.95	10.36	3.05	10.89
Total Debt	2.49	2.79	0	0	8.66
Debt Growth	-10.61%	-	-	-	-
Retained Earnings	-263.82	-177.74	-106.28	-38.4	-26.36
Comprehensive Income	-9.67	-10.14	-1.49	1.96	1.3
Shareholders' Equity	133.16	138.85	211.92	-35.3	-23.53
Net Cash / Debt	140.7	139.8	211.53	3.41	-0.82
Net Cash / Debt Growth	0.64%	-33.91%	6112.36%	-	-
Net Cash Per Share	3.23	4.85	48.79	19.22	-4.61
Working Capital	131.54	137.54	211.43	2.59	-1.44
Book Value Per Share	3.06	4.82	48.88	-199.23	-132.79

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).